Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Develops New Phase IIa Alzheimer\u2019s Trial Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vivoryon Therapeutics"},{"company":"Algiax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algiax Pharmaceuticals Enrolles First Patient in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Algiax Pharmaceuticals"},{"company":"Evonik Industries","sponsor":"Cassava Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik and Cassava Sciences Join Forces to Fight Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evonik Industries"},{"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vivoryon Therapeutics"}]

Evonik Industries

Contact Supplier

Our CMO solutions- we specialize where you need us most!

Contact Supplier

Contact Supplier

Digital Content

Evonik and Cassava Sciences Join Forces to Fight Alzheimer’s Disease

Details:

Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.

Lead Product(s): Simufilam

Therapeutic Area: Neurology Product Name: PTI-125

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Cassava Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 09, 2021

Evonik company banner

2022 Fall Technical Meeting

Attending

envelop Contact Supplier

Vivoryon Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O...

Details:

Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.

Lead Product(s): Varoglutamstat

Therapeutic Area: Neurology Product Name: PQ912

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Nordic Bioscience

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2022

ASK
US

Upload
your Pipeline Activity

Algiax Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Algiax Pharmaceuticals Enrolles First Patient in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain

Details:

The CURE study is a randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety after repeated oral dosing of Algiax´ lead product AP-325.

Lead Product(s): AP-325

Therapeutic Area: Neurology Product Name: AP-325

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 21, 2020

ASK
US

Upload
your Pipeline Activity

Vivoryon Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Vivoryon Develops New Phase IIa Alzheimer’s Trial Design

Details:

Vivoryon and the Alzheimer’s Disease Cooperative Study have developed a new trial design for Phase 2a Alzheimer’s trial in the US as a stage gate to Phase 2b. Vivoryon’s lead candidate, PQ912, got approval of the International Nonproprietary Name (INN), varoglutamstat.

Lead Product(s): Varoglutamstat

Therapeutic Area: Neurology Product Name: PQ912

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY